<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xml:lang="EN" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Res Cardiol</journal-id><journal-title>Clinical Research in Cardiology</journal-title><issn pub-type="ppub">1861-0684</issn><issn pub-type="epub">1861-0692</issn><publisher><publisher-name>D. Steinkopff-Verlag</publisher-name><publisher-loc>Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19301059</article-id><article-id pub-id-type="pmc">2698968</article-id><article-id pub-id-type="publisher-id">12</article-id><article-id pub-id-type="doi">10.1007/s00392-009-0012-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Recent in vitro findings of negative inotropy of pantoprazole did not translate into clinically relevant effects on left ventricular function in healthy volunteers</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Schillinger</surname><given-names>Wolfgang</given-names></name><address><phone>+49-551-3922920</phone><fax>+49-551-399804</fax><email>Wolfgang.Schillinger@medizin.uni-goettingen.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>H&#x000f6;rnes</surname><given-names>Nina</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Teucher</surname><given-names>Nils</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sossalla</surname><given-names>Samuel</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sehrt</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jung</surname><given-names>Klaus</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>H&#x000fc;nlich</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Uns&#x000f6;ld</surname><given-names>Bernhard</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Geiling</surname><given-names>Bianca</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ramadori</surname><given-names>Giuliano</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hilgers</surname><given-names>Reinhard</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schw&#x000f6;rer</surname><given-names>Harald</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hasenfuss</surname><given-names>Gerd</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Herzzentrum, Kardiologie und Pneumologie, Universit&#x000e4;tsmedizin G&#x000f6;ttingen, Robert-Koch-Str. 40, 37099 G&#x000f6;ttingen, Germany </aff><aff id="Aff2"><label>2</label>Herzzentrum, Thorax-, Herz- und Gef&#x000e4;&#x000df;chirurgie, Universit&#x000e4;tsmedizin G&#x000f6;ttingen, G&#x000f6;ttingen, Germany </aff><aff id="Aff3"><label>3</label>Zentrum Pharmakologie und Toxikologie, Klinische Pharmakologie, Universit&#x000e4;tsmedizin G&#x000f6;ttingen, G&#x000f6;ttingen, Germany </aff><aff id="Aff4"><label>4</label>Medizinische Statistik, Universit&#x000e4;tsmedizin G&#x000f6;ttingen, G&#x000f6;ttingen, Germany </aff><aff id="Aff5"><label>5</label>Genetische Epidemiologie, Universit&#x000e4;tsmedizin G&#x000f6;ttingen, G&#x000f6;ttingen, Germany </aff><aff id="Aff6"><label>6</label>Gastroenterologie und Endokrinologie, Universit&#x000e4;tsmedizin G&#x000f6;ttingen, G&#x000f6;ttingen, Germany </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>3</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2009</year></pub-date><volume>98</volume><issue>6</issue><fpage>391</fpage><lpage>399</lpage><history><date date-type="received"><day>4</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>24</day><month>2</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2009</copyright-statement></permissions><abstract xml:lang="EN"><sec><title>Purpose</title><p>Reports on cardiac problems with oral proton pump inhibitors have caused extensive safety reviews by the US Food and Drug Administration. We provide additional data on acute cardiac effects of an intravenous application.</p></sec><sec><title>Methods</title><p>Echocardiography was performed in 18 healthy volunteers after administration of a common high-dose regimen of pantoprazole (80&#x000a0;mg i.v. bolus followed by 8&#x000a0;mg/h for 1&#x000a0;h) or placebo.</p></sec><sec><title>Design</title><p>The design included a randomized, double-blind, placebo-controlled cross-over trial.</p></sec><sec><title>Results</title><p>Ejection fraction (%, mean&#x000a0;&#x000b1;&#x000a0;SE) in the treatment group (placebo group) was 60.7&#x000a0;&#x000b1;&#x000a0;1.1 (61.2&#x000a0;&#x000b1;&#x000a0;1.7) at baseline, and 62.6&#x000a0;&#x000b1;&#x000a0;1.1 (62.1&#x000a0;&#x000b1;&#x000a0;1.9), 64.7&#x000a0;&#x000b1;&#x000a0;1.6 (63.5&#x000a0;&#x000b1;&#x000a0;1.3), 62.6&#x000a0;&#x000b1;&#x000a0;1.6 (61.0&#x000a0;&#x000b1;&#x000a0;1.6) and 63.0&#x000a0;&#x000b1;&#x000a0;1.4 (61.8&#x000a0;&#x000b1;&#x000a0;1.5) at 7.5, 15, 30 and 60&#x000a0;min after bolus application, respectively (<italic>p</italic>&#x000a0;=&#x000a0;n.s.). Similarly, no significant changes were found for cardiac output, cardiac index, blood pressure and heart rate. In contrast, gastric pH that was used as a treatment control was significantly increased 60&#x000a0;min after the application of pantoprazole as compared to baseline and to placebo.</p></sec><sec><title>Conclusions</title><p>Pantoprazole as injection is safe in healthy subjects with respect to cardiac contractile function. However, in view of recent reports of negative inotropy of the drug, further studies in heart failure patients are required.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Cardiac output</kwd><kwd>Myocardial contraction</kwd><kwd>Heart failure</kwd><kwd>Cardiotonic agents</kwd><kwd>Pharmacology</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2009</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Proton pump inhibitors (PPIs) are extensively used in the treatment of acid-related gastrointestinal diseases [<xref ref-type="bibr" rid="CR28">28</xref>]. In Germany, anti-ulcer/gastrointestinal reflux products accounted for &#x020ac;1.4 billion gross pharmacy sales in 2007, and two different PPIs ranked among the 15 top-selling drugs [<xref ref-type="bibr" rid="CR9">9</xref>]. Three PPIs, namely pantoprazole, omeprazole and esomeprazole, are currently available as intravenous formulations in Europe. The rationale for use has come primarily with the suggested efficacy in reducing rebleeding after endoscopic treatment of bleeding peptic ulcers (e.g., 19, 30). The target goal for gastric pH in these patients has been suggested to be &#x0003e;6 in order to promote hemostasis and minimize clot lysis, in contradistinction to the target pH of &#x0003e;4 for preventing stress ulcer in patients, or healing ulcers or reflux esophagitis. As such, the dosing amounts of i.v. PPIs have been higher than that of oral PPIs [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p><p>Yet, it has been known for several years that the effects of PPIs are not strictly limited to gastric parietal cells. Relaxation of smooth muscle cells has been implicated from experiments with human and guinea pig airway smooth muscle [<xref ref-type="bibr" rid="CR23">23</xref>] and isolated arteries from rats [<xref ref-type="bibr" rid="CR21">21</xref>], guinea pigs and humans [<xref ref-type="bibr" rid="CR23">23</xref>]. Moreover, we have recently demonstrated negative inotropy of pantoprazole in isolated myocardium of humans and rabbits [<xref ref-type="bibr" rid="CR25">25</xref>]. This was dose-dependent, induced nearly complete inhibition of twitch force at high-doses and was partially reversible. Similar results have been obtained with esomeprazole, which is suggestive of a class effect of PPIs. The subcellular mechanisms of cardiac effects of pantoprazole were distinct from the effects in gastric cells and involved changes in intracellular Ca<sup>2+</sup> transients and impaired Ca<sup>2+</sup> responsiveness of the myofilaments. Also, we have deduced from the in vitro findings that negative inotropy may be of clinical relevance when using common therapeutic doses [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p>Recent reports on heart-related problems in two small, long-term clinical studies of patients treated with oral PPIs for severe gastroesophageal reflux disease have caused extensive safety reviews by the US Food and Drug Administration (FDA). On December 10, 2007, the FDA concluded that long-term use of oral omeprazole or esomeprazole is not likely to be associated with an increased risk of heart problems [<xref ref-type="bibr" rid="CR6">6</xref>]. However, none of the evaluated studies was specifically conducted to assess the risk of heart problems and patient follow-up was incomplete. Moreover, studies investigating the acute effects of intravenous high-dose PPIs on left ventricular function are missing. The present study investigated the effects of i.v. pantoprazole on left ventricular function in healthy volunteers using a common high-dose regimen [<xref ref-type="bibr" rid="CR30">30</xref>]. Echocardiography was used because in clinical practice, the vast majority of clinical decisions involving left ventricular function are based on echocardiographic findings.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Participants</title><p>Enrollment of test persons was performed from 15 May 2005 until 27 January 2006 in the Department of Cardiology and Pneumology, University Medical Center G&#x000f6;ttingen, Germany. For inclusion and exclusion criteria, see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Volunteers were thoroughly examined and routine laboratory parameters, ECG recordings and echocardiography were analyzed. Volunteers were excluded if any pathologic finding was present. Moreover, only subjects with excellent sonographic conditions were included. For baseline characteristics, see Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. The study complies with the Declaration of Helsinki. The ethics committee of the University of G&#x000f6;ttingen approved the research protocol and informed consent was obtained from all subjects.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Inclusion and exclusion criteria</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Inclusion criteria</th><th align="left">Exclusion criteria</th></tr></thead><tbody><tr><td align="left">Age, 18&#x02013;40&#x000a0;years</td><td align="left">History of cardiac disease</td></tr><tr><td align="left">No clinically overt signs of heart failure</td><td align="left">History of other relevant pre-existing illness</td></tr><tr><td align="left">Echocardiographic ejection fraction &#x02265;55%</td><td align="left">Pathologic findings in clinical examinations</td></tr><tr><td align="left">Excellent sonographic conditions</td><td align="left">Pathologic echocardiographic findings</td></tr><tr><td align="left">Non-smoker</td><td align="left">Pathologic ECG findings</td></tr><tr><td align="left"/><td align="left">Pathologic laboratory findings</td></tr><tr><td align="left"/><td align="left">Pregnancy and lactation</td></tr><tr><td align="left"/><td align="left">No or insufficient contraception</td></tr><tr><td align="left"/><td align="left">Intolerance of pantoprazole</td></tr><tr><td align="left"/><td align="left">Alcohol or drug abuse</td></tr></tbody></table></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Baseline characteristics of healthy volunteers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">All<break/><italic>n</italic>&#x000a0;=&#x000a0;18</th><th align="left">Female<break/><italic>n</italic>&#x000a0;=&#x000a0;9</th><th align="left">Male<break/><italic>n</italic>&#x000a0;=&#x000a0;9</th><th align="left">Protocol 1<break/><italic>n</italic>&#x000a0;=&#x000a0;9</th><th align="left">Protocol 2<break/><italic>n</italic>&#x000a0;=&#x000a0;9</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td char="&#x000b1;" align="char">24.3&#x000a0;&#x000b1;&#x000a0;0.4</td><td char="&#x000b1;" align="char">24.0&#x000a0;&#x000b1;&#x000a0;0.4</td><td char="&#x000b1;" align="char">24.6&#x000a0;&#x000b1;&#x000a0;0.8</td><td char="&#x000b1;" align="char">24.1&#x000a0;&#x000b1;&#x000a0;0.4</td><td char="&#x000b1;" align="char">24.4&#x000a0;&#x000b1;&#x000a0;0.8</td></tr><tr><td align="left">Body mass index (kg/m&#x000b2;)</td><td char="&#x000b1;" align="char">22.7&#x000a0;&#x000b1;&#x000a0;0.4</td><td char="&#x000b1;" align="char">21.5&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="&#x000b1;" align="char">23.8&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="&#x000b1;" align="char">22.7&#x000a0;&#x000b1;&#x000a0;0.6</td><td char="&#x000b1;" align="char">22.6&#x000a0;&#x000b1;&#x000a0;0.6</td></tr><tr><td align="left">Body surface area (m&#x000b2;)</td><td char="&#x000b1;" align="char">1.87&#x000a0;&#x000b1;&#x000a0;0.03</td><td char="&#x000b1;" align="char">1.75&#x000a0;&#x000b1;&#x000a0;0.01</td><td char="&#x000b1;" align="char">1.99&#x000a0;&#x000b1;&#x000a0;0.03</td><td char="&#x000b1;" align="char">1.85&#x000a0;&#x000b1;&#x000a0;0.05</td><td char="&#x000b1;" align="char">1.89&#x000a0;&#x000b1;&#x000a0;0.05</td></tr><tr><td align="left" colspan="6">Resting blood pressure (mmHg)</td></tr><tr><td align="left">&#x000a0;Systolic</td><td char="&#x000b1;" align="char">121.3&#x000a0;&#x000b1;&#x000a0;1.6</td><td char="&#x000b1;" align="char">118.3&#x000a0;&#x000b1;&#x000a0;2.4</td><td char="&#x000b1;" align="char">124.2&#x000a0;&#x000b1;&#x000a0;2.0</td><td char="&#x000b1;" align="char">121.7&#x000a0;&#x000b1;&#x000a0;2.6</td><td char="&#x000b1;" align="char">120.8&#x000a0;&#x000b1;&#x000a0;2.0</td></tr><tr><td align="left">&#x000a0;Diastolic</td><td char="&#x000b1;" align="char">69.2&#x000a0;&#x000b1;&#x000a0;1.7</td><td char="&#x000b1;" align="char">70.4&#x000a0;&#x000b1;&#x000a0;2.2</td><td char="&#x000b1;" align="char">67.9&#x000a0;&#x000b1;&#x000a0;2.5</td><td char="&#x000b1;" align="char">72.1&#x000a0;&#x000b1;&#x000a0;2.5</td><td char="&#x000b1;" align="char">66.3&#x000a0;&#x000b1;&#x000a0;2.1</td></tr><tr><td align="left">Resting heart rate (/min)</td><td char="&#x000b1;" align="char">66.8&#x000a0;&#x000b1;&#x000a0;1.5</td><td char="&#x000b1;" align="char">66.6&#x000a0;&#x000b1;&#x000a0;2.1</td><td char="&#x000b1;" align="char">67.1&#x000a0;&#x000b1;&#x000a0;2.1</td><td char="&#x000b1;" align="char">65.9&#x000a0;&#x000b1;&#x000a0;2.1</td><td char="&#x000b1;" align="char">67.8&#x000a0;&#x000b1;&#x000a0;2.0</td></tr><tr><td align="left">Resting ejection fraction (%)</td><td char="&#x000b1;" align="char">60.9&#x000a0;&#x000b1;&#x000a0;1.0</td><td char="&#x000b1;" align="char">61.4&#x000a0;&#x000b1;&#x000a0;1.4</td><td char="&#x000b1;" align="char">60.4&#x000a0;&#x000b1;&#x000a0;1.5</td><td char="&#x000b1;" align="char">60.5&#x000a0;&#x000b1;&#x000a0;1.4</td><td char="&#x000b1;" align="char">61.3&#x000a0;&#x000b1;&#x000a0;1.5</td></tr></tbody></table><table-wrap-foot><p>Mean baseline characteristics (&#x000b1;SE) of 18 volunteers are shown. Protocol 1 means persons who were randomized to receive pantoprazole on day 1 and placebo on day 2, and protocol 2 inversely. There were no statistically significant differences between groups</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>Study design, sample size and randomization</title><p>A double-blind, placebo-controlled cross-over design was applied [<xref ref-type="bibr" rid="CR27">27</xref>]. The sample size was calculated according to the change in ejection fraction (EF) as an effect of pantoprazole that was meant to be detected. The expected standard deviation was derived from historical data [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Assuming a power of 0.90 and an alpha-level of 0.05, we calculated that 14 subjects would be sufficient for the detection of an absolute difference in EF of 6%. To allow for dropout, ten females and ten males were randomized. Half of each gender group received pantoprazole on study day 1 and placebo on study day 2 (protocol 1), and the other half inversely (protocol 2). Stratified block randomization was used to balance the number of men and women (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). During the preliminary examination, a treatment time was assigned to each participant. From this treatment time, a study number was derived, where each study number was assigned to one of the two groups by the statistician beforehand. Two subjects, one female and one male, dropped out because of drug mixup on study day 2.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Flowchart of participation in the study</p></caption><graphic position="anchor" xlink:href="392_2009_12_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec5"><title>Pharmaceuticals</title><p>Pantoprazole sodium powder for injection was purchased from Altana Pharma AG, Konstanz, Germany. NaCl 0.9% was purchased from DeltaSelect GmbH, Pfullingen, Germany. Preparations of test substances were of identical aspect and were done by the pharmacy of the University Medical Center G&#x000f6;ttingen, where also the randomization list was kept.</p></sec><sec id="Sec6"><title>Gastric pH</title><p>For gastric pH measurement, a Slimline<sup>&#x000ae;</sup> single-use pH catheter (Medtronic GmbH, D&#x000fc;sseldorf, Germany) connected to a Digitrapper&#x02122; pH 400 recorder (Medtronic GmbH, D&#x000fc;sseldorf, Germany) was used. The display was covered to exclude examiner bias during further measurements. After the study procedure, data were read with Polygram Net&#x02122; 4.01 software (Medtronic GmbH, D&#x000fc;sseldorf, Germany). Analyses were performed computerized after completion of the trial.</p></sec><sec id="Sec7"><title>Holter ECG</title><p>Holter ECG was recorded using a Lifecard CF digital Holter recorder (Spacelabs Healthcare GmbH, Feucht, Germany). Digital data were analyzed after completion of the trial by Pathfinder Digital software (Spacelabs Healthcare GmbH, Feucht, Germany). The mean heart rates for 1-min-intervals were calculated.</p></sec><sec id="Sec8"><title>Blood pressure</title><p>Non-invasive blood pressure measurements were done using an automatic inflation blood pressure monitor Omron 705IT (Omron Medizintechnik GmbH, Mannheim, Germany).</p></sec><sec id="Sec9"><title>Echocardiography</title><p>2D- and continuous wave (CW) Doppler echocardiography with standard axis views were performed by one highly experienced cardiologist using a Sonos 7500 (Philips Medizin Systeme GmbH, Hamburg, Germany) ultrasound machine according to the recommendations of the American Society of Echocardiography [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. For volume measurements, three loops in the apical 4-chamber view were digitally saved at each sample interval during quiet respiration. For measurement of velocity&#x02013;time integral (VTI), the transducer was angulated to position the path of the CW Doppler in line with the left ventricular outflow tract (LVOT). Three velocity signals at each sample interval were saved. For measurement of LVOT diameter (<italic>D</italic><sub>LVOT</sub>), three beats in the parasternal long axis view zoomed on the aortic valve were placed in a cine-loop. <italic>D</italic><sub>LVOT</sub> was measured at the base of the aortic cusps at peak of systole (aortic valve maximally open), using inner edge to inner edge. The largest of the three measurements was taken and was further used in all serial measurements.</p><p>Analyses were performed blinded after completion of the trial using Philips Xcelera 1.2 L4 software (Philips Medizin Systeme GmbH, Hamburg, Germany). Left ventricular volumes were calculated according to the single-plane method of discs [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. End-diastole was defined as the frame in which the QRS complex appeared. End-systole was defined by the frame preceding initial early diastolic mitral opening, which corresponded to the smallest visible cavity area. EF was calculated as<disp-formula id="Equa"><tex-math id="M1">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$ {\text{EF (}}\% )= 100 \times ({\text{EDV}} - {\text{ESV}})/{\text{EDV}} . $$\end{document}</tex-math></disp-formula></p><p>Cross-sectional area (CSA) of LVOT was calculated as<disp-formula id="Equb"><tex-math id="M2">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$ {\text{CSA(cm}}^{2} )= D_{\text{LVOT}}^{2} \times \pi /4. $$\end{document}</tex-math></disp-formula></p><p>Measurements of CW Doppler velocities were taken from the outer border and the velocity&#x02013;time integral (VTI) was measured. CO was calculated as<disp-formula id="Equc"><tex-math id="M3">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$ {\text{CO (L}}/\min )= ({\text{CSA}} \times {\text{VTI}} \times {\text{HR}})/1000 $$\end{document}</tex-math></disp-formula>at which heart rate (HR) was averaged over 1&#x000a0;min at each sample interval [<xref ref-type="bibr" rid="CR22">22</xref>]. Averaged heart rates were similar to the respective instantaneous heart rates measured with the echo machine or the blood pressure monitor. CI was calculated as<disp-formula id="Equd"><tex-math id="M4">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$ {\text{CI [L}}/(\min \times {\text{m}}^{2} ) ]= {\text{CO}}/{\text{BSA}} $$\end{document}</tex-math></disp-formula>and body surface area (BSA) was calculated from height and weight according to the formula of DuBois and DuBois [<xref ref-type="bibr" rid="CR4">4</xref>].</p></sec><sec id="Sec10"><title>Interventions and blinding</title><p>Pantoprazole 80&#x000a0;mg given intravenously over 2&#x000a0;min, followed by 8&#x000a0;mg/h [<xref ref-type="bibr" rid="CR30">30</xref>] was applied by a Perfusor fm (B. Braun AG, Melsungen, Germany). Alternatively, NaCl 0.9% was applied in an identical manner. The test subject as well as the examiner and all assistant personnel were blinded toward the nature of the test substance. All parameters were measured 5&#x02013;10&#x000a0;min before bolus application (baseline, BL) and 7.5, 15, 30 and 60&#x000a0;min (echocardiography, blood pressure) or continuously thereafter (gastric pH, Holter ECG). Adverse reactions were noted and the intensity was quantified by a numeric analog scale ranging from 1 to 10. Examination with the comparator substance was done after at least 5 and not later than after 14&#x000a0;days.</p></sec><sec id="Sec11"><title>Statistical methods</title><p>Classical cross-over analyses, which account for treatment, period and carry-over effects [<xref ref-type="bibr" rid="CR27">27</xref>] were performed separately for each point in time. Neither of these effects was statistically significant at an alpha-level of 0.05 (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). In particular, the estimated treatment effects on EF at the single times reached from &#x02212;1.2 to 0.7, which is below the expected effect of 6%. For calculating the true power of the cross-over analyses for the detection of EF-changes under treatment, we determined the standard deviation of the measured EFs and proceeded as in the sampling frame. Thus, we received a power of 0.98 for the detection of changes of 6% with the remaining 18 subjects.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Hemodynamics with pantoprazole</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="3">Mean (&#x000b1;SE)</th><th align="left" colspan="3"><italic>p</italic> values of evaluated effects</th></tr><tr><th align="left">Time (min)</th><th align="left">Pantoprazole<break/><italic>n</italic>&#x000a0;=&#x000a0;18</th><th align="left">Placebo<break/><italic>n</italic>&#x000a0;=&#x000a0;18</th><th align="left">Carry-over</th><th align="left">Treatment</th><th align="left">Period</th></tr></thead><tbody><tr><td align="left" rowspan="5">EF (%)</td><td align="left">BL</td><td char="&#x000b1;" align="char">60.7&#x000a0;&#x000b1;&#x000a0;1.1</td><td char="&#x000b1;" align="char">61.2&#x000a0;&#x000b1;&#x000a0;1.7</td><td char="." align="char">0.55</td><td char="." align="char">0.69</td><td char="." align="char">0.69</td></tr><tr><td align="left">7.5</td><td char="&#x000b1;" align="char">62.6&#x000a0;&#x000b1;&#x000a0;1.0</td><td char="&#x000b1;" align="char">62.1&#x000a0;&#x000b1;&#x000a0;1.9</td><td char="." align="char">0.85</td><td char="." align="char">0.54</td><td char="." align="char">0.29</td></tr><tr><td align="left">15</td><td char="&#x000b1;" align="char">64.7&#x000a0;&#x000b1;&#x000a0;1.6</td><td char="&#x000b1;" align="char">63.5&#x000a0;&#x000b1;&#x000a0;1.3</td><td char="." align="char">0.43</td><td char="." align="char">0.57</td><td char="." align="char">0.09</td></tr><tr><td align="left">30</td><td char="&#x000b1;" align="char">62.6&#x000a0;&#x000b1;&#x000a0;1.6</td><td char="&#x000b1;" align="char">61.0&#x000a0;&#x000b1;&#x000a0;1.6</td><td char="." align="char">0.46</td><td char="." align="char">0.73</td><td char="." align="char">0.23</td></tr><tr><td align="left">60</td><td char="&#x000b1;" align="char">63.0&#x000a0;&#x000b1;&#x000a0;1.4</td><td char="&#x000b1;" align="char">61.8&#x000a0;&#x000b1;&#x000a0;1.5</td><td char="." align="char">0.88</td><td char="." align="char">0.96</td><td char="." align="char">0.70</td></tr><tr><td align="left" rowspan="5">CO (L/min)</td><td align="left">BL</td><td char="&#x000b1;" align="char">5.7&#x000a0;&#x000b1;&#x000a0;0.3</td><td char="&#x000b1;" align="char">5.3&#x000a0;&#x000b1;&#x000a0;0.2</td><td char="." align="char">0.08</td><td char="." align="char">0.29</td><td char="." align="char">0.31</td></tr><tr><td align="left">7.5</td><td char="&#x000b1;" align="char">5.7&#x000a0;&#x000b1;&#x000a0;0.2</td><td char="&#x000b1;" align="char">5.5&#x000a0;&#x000b1;&#x000a0;0.3</td><td char="." align="char">0.60</td><td char="." align="char">0.38</td><td char="." align="char">0.41</td></tr><tr><td align="left">15</td><td char="&#x000b1;" align="char">5.5&#x000a0;&#x000b1;&#x000a0;0.3</td><td char="&#x000b1;" align="char">5.3&#x000a0;&#x000b1;&#x000a0;0.2</td><td char="." align="char">0.39</td><td char="." align="char">0.23</td><td char="." align="char">0.88</td></tr><tr><td align="left">30</td><td char="&#x000b1;" align="char">5.6&#x000a0;&#x000b1;&#x000a0;0.3</td><td char="&#x000b1;" align="char">5.5&#x000a0;&#x000b1;&#x000a0;0.2</td><td char="." align="char">0.68</td><td char="." align="char">0.80</td><td char="." align="char">0.30</td></tr><tr><td align="left">60</td><td char="&#x000b1;" align="char">5.5&#x000a0;&#x000b1;&#x000a0;0.3</td><td char="&#x000b1;" align="char">5.6&#x000a0;&#x000b1;&#x000a0;0.2</td><td char="." align="char">0.75</td><td char="." align="char">0.31</td><td char="." align="char">0.47</td></tr><tr><td align="left" rowspan="5">CI [L/(min&#x000a0;m&#x000b2;)]</td><td align="left">BL</td><td char="&#x000b1;" align="char">3.0&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">2.8&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="." align="char">0.05</td><td char="." align="char">0.38</td><td char="." align="char">0.22</td></tr><tr><td align="left">7.5</td><td char="&#x000b1;" align="char">3.0&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">3.0&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="." align="char">0.61</td><td char="." align="char">0.54</td><td char="." align="char">0.40</td></tr><tr><td align="left">15</td><td char="&#x000b1;" align="char">2.9&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">2.8&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="." align="char">0.35</td><td char="." align="char">0.25</td><td char="." align="char">0.81</td></tr><tr><td align="left">30</td><td char="&#x000b1;" align="char">3.0&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">2.9&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="." align="char">0.61</td><td char="." align="char">0.87</td><td char="." align="char">0.16</td></tr><tr><td align="left">60</td><td char="&#x000b1;" align="char">2.9&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">3.0&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="." align="char">0.79</td><td char="." align="char">0.42</td><td char="." align="char">0.38</td></tr></tbody></table><table-wrap-foot><p>Mean (&#x000b1;SE) are shown. No statistically significant differences were found</p><p>BL baseline, EF ejection fraction, CO cardiac output, CI cardiac index</p></table-wrap-foot></table-wrap></p><p>As there was no significant carry-over effect, we combined the two periods and modeled both EF and CI, as a mixture of treatment- and time-effect as well as a (treatment&#x000a0;&#x000d7;&#x000a0;time)-interaction. Again, no significant effect could be detected at an alpha-level of 0.05 (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). pH values between treatment and control group (or between times) were compared by an analysis of variance for longitudinal data. All analyses were carried out using the statistic software R and SAS. Data are presented as mean&#x000a0;&#x000b1;&#x000a0;SE.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p><italic>p</italic> values in the mixture model analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Treatment</th><th align="left">Point in time</th><th align="left">Interaction (treatment&#x000a0;&#x000d7;&#x000a0;point in time)</th></tr></thead><tbody><tr><td align="left">EF</td><td char="." align="char">0.46</td><td char="." align="char">0.07</td><td char="." align="char">1.0</td></tr><tr><td align="left">CI</td><td char="." align="char">0.30</td><td char="." align="char">0.42</td><td char="." align="char">0.49</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec12" sec-type="results"><title>Results</title><sec id="Sec13"><title>Basic clinical parameters and adverse reactions</title><p>Systolic and diastolic blood pressure measured non-invasively did not show any statistically significant differences over 60&#x000a0;min after application of pantoprazole as compared to baseline or to placebo. Similarly, heart rate, which was averaged over 1&#x000a0;min at each sample interval did not demonstrate any statistically significant change as a result of treatment with pantoprazole or placebo (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Test substances were well tolerated and test persons reported few adverse reactions. Irritation of the throat by the pH catheter was reported by seven persons with an intensity of 1&#x02013;5, irritation of the injection site by three (intensity 2&#x02013;3), abdominal pain by two (2&#x02013;3), sweetish taste by one (1), and heartburn by one person (2) on a scale of 1&#x02013;10 each. There was no significant increase of adverse reactions as a result of treatment with pantoprazole compared to placebo.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Mean&#x000a0;&#x000b1;&#x000a0;SE of systolic and diastolic blood pressure (<bold>a</bold>) and of heart rate (<bold>b</bold>) at baseline (BL) and during application of a pantoprazole high-dose regimen (cf. &#x0201c;<xref rid="Sec2" ref-type="sec">Materials and methods</xref>&#x0201d;) as compared to placebo (<italic>n</italic>&#x000a0;=&#x000a0;18 each)</p></caption><graphic position="anchor" xlink:href="392_2009_12_Fig2_HTML" id="MO6"/></fig></p></sec><sec id="Sec14"><title>Left ventricular ejection fraction, cardiac output and cardiac index</title><p>Results of echocardiographic evaluation of left ventricular function in the presence of pantoprazole or placebo are summarized in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. There was no statistically significant change in left ventricular EF over 60&#x000a0;min in subjects receiving a common dosing regimen of pantoprazole when compared to baseline measurements before bolus application. Also, no significant differences in EF were found when compared to placebo infused to the same subjects in an identical manner. In addition, there were no significant changes in CO and CI over 60&#x000a0;min as a result of pantoprazole infusion compared to baseline or compared to placebo.</p></sec><sec id="Sec15"><title>Gastric pH</title><p>Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> demonstrates a typical gastric pH profile under treatment with pantoprazole or placebo in the same subject and statistical data of all subjects. At 60&#x000a0;min after the bolus application of pantoprazole, gastric pH was 3.9&#x000a0;&#x000b1;&#x000a0;0.5. This was significantly different from baseline (1.6&#x000a0;&#x000b1;&#x000a0;0.1, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and from placebo (1.7&#x000a0;&#x000b1;&#x000a0;0.3, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). However, it should be mentioned that the measurement of gastric pH does not reflect actual acid secretion, but actual acid content, which depends on peristalsis and is not directly influenced by pantoprazole. In a recent study, acid secretion was fully inhibited within 1&#x000a0;h after administration of 80&#x000a0;mg of pantoprazole [<xref ref-type="bibr" rid="CR7">7</xref>]. In the present study, an increase in pH usually occurred 30&#x02013;45&#x000a0;min after administration. In some subjects, no increase in pH was seen in the observation period. This was ascribed to test conditions with subjects having fasted for at least 4&#x000a0;h and lying quietly on the left lateral decubitus during the observation period. These hampered or slowed down the emptying of the gastric acid to the duodenum. In other subjects receiving placebo, pH alternated between acidic and neutral values, reflecting temporal loss of contact of the pH catheter with gastric acid because of gastric peristalsis.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Original recordings of typical gastric pH profiles of a healthy subject under treatment with pantoprazole (<bold>a</bold>) or placebo (<bold>b</bold>). <bold>c</bold><italic>Box</italic><italic>and</italic><italic>whiskers plots</italic> showing median pH and 25&#x02013;75% quartiles of gastric pH in healthy volunteers under treatment with pantoprazole or placebo at baseline (BL) and after 60&#x000a0;min. Outliers are marked with <italic>circles</italic> (<italic>n</italic>&#x000a0;=&#x000a0;18 each)</p></caption><graphic position="anchor" xlink:href="392_2009_12_Fig3_HTML" id="MO7"/></fig></p></sec></sec><sec id="Sec16" sec-type="discussion"><title>Discussion</title><p>The present study shows that a common high-dose regimen of pantoprazole (80&#x000a0;mg over 2&#x000a0;min followed by 8&#x000a0;mg/h i.v.), usually applied for reducing rebleeding after endoscopic treatment of bleeding peptic ulcers [<xref ref-type="bibr" rid="CR30">30</xref>], did not result in clinically relevant impairment of left ventricular function and hemodynamics in healthy volunteers. We demonstrated that left ventricular EF did not significantly change over 60&#x000a0;min after application of pantoprazole as compared to baseline or to placebo. Also, no significant changes in cardiac output, cardiac index or any basic hemodynamic parameter were found. In contrast, gastric pH that was used as a treatment control was significantly increased 60&#x000a0;min after the application of pantoprazole as compared to baseline and to placebo.</p><sec id="Sec17"><title>Pharmacology of PPIs</title><p>With respect to gastric proton pump inhibition, all PPIs are prodrugs and require activation by protonation at low pH. Following activation, PPIs undergo a series of chemical reactions that culminate in covalent binding to the gastric proton pump. Moreover, protonation converts the drug from a lipophilic to a hydrophilic form that can no longer permeate cell membranes. For these reasons, in parietal cells, PPIs become trapped after protonation and exhibit a substantial accumulation versus plasma at low pH, making the inhibitory effect of PPIs on proton pumps independent of plasma concentrations [<xref ref-type="bibr" rid="CR28">28</xref>]. Recently, our group has reported on negative inotropy of pantoprazole in isolated myocardium of humans and rabbits [<xref ref-type="bibr" rid="CR25">25</xref>]. In contrast to the subcellular mechanisms of PPIs in gastric cells, the effects in myocardium were suggested to be independent of activation at low pH, because negative inotropy occurred at pH 7.3&#x02013;7.4. Moreover, in contrast to proton pump inhibition, the effects in the myocardium were at least partially reversible within few minutes after washout of the drug. Hence, we concluded that the potential effects of PPIs on contractile function in vivo may depend on plasma concentrations of the unprotonated native drug. However, in vivo PPIs are quickly eliminated from blood with plasma elimination half-lives of about 1&#x02013;2&#x000a0;h [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. We therefore anticipated that in the present study, the potential impairment of left ventricular function during an identical infusion regimen of pantoprazole should be maximum at the time of maximum plasma concentrations, i.e., shortly after bolus application. For the same reason, no extended observations over several hours or days were performed in the present study.</p></sec><sec id="Sec18"><title>Reasons for the absence of clinically relevant cardiac effects</title><p>What might be the potential reasons for the absence of a clinically relevant effect of pantoprazole on cardiac performance and hemodynamics in the present study in view of our recent findings in isolated myocardium? It is obvious that one has to be cautious in extrapolating in vitro findings to the clinical situation, because findings seen directly on the myocardial level may be masked in vivo by physiological effects such as preload, afterload, neurohumoral activation and heart rate. In this regard, it is noteworthy that heart rate was unchanged, which might have been indicative of an increased sympathetic tone as a compensatory mechanism. Moreover, cardiac side effects may be attenuated in vivo, because the activity of the free compound may be substantially lower because of high plasma protein binding. Recently, although 40&#x000a0;mg pantoprazole gave a serum concentration&#x02013;time curve (AUC) of the total parent compound of 10.5&#x000a0;&#x003bc;mol&#x000a0;h/L, the high plasma protein binding of pantoprazole of 98% reversed the AUC value for the free drug to 0.19&#x000a0;&#x003bc;mol&#x000a0;h/L [<xref ref-type="bibr" rid="CR17">17</xref>]. Yet, PPIs show characteristic pharmacokinetic properties that may specifically influence the potency of cardiac effects. For example, the fraction of drug unbound to plasma was reported as: omeprazole 0.05, esomeprazole 0.05, rabeprazole 0.04, lansoprazole 0.03 and pantoprazole 0.02 [<xref ref-type="bibr" rid="CR28">28</xref>]. Greater fraction of active free compound might therefore indicate superior potency with regard to cardiac effects.</p></sec><sec id="Sec19"><title>Accuracy of methods</title><p>One might argue that the accuracy of echocardiography was not sufficient for the detection of small changes in left ventricular EF. However, during the last decades, echocardiographic methods and techniques have improved and expanded dramatically. It was shown that echocardiography can be performed with a high degree of reproducibility and that it was a reliable tool for the quantification of left ventricular function in numerous clinical trials [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Poor endocardial definition, the most frequent pitfall in 2D echocardiographic evaluation of left ventricular function [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR22">22</xref>], was circumvented in the present study by only including subjects with excellent imaging conditions. Recently, in clinical trials, changes in left ventricular EF of 6&#x02013;9% were detected by echocardiography in patients with congestive heart failure under treatment with &#x003b2;-blockers, which have been considered as clinically relevant [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. The present study was powered to detect changes in left ventricular EF of at least 6% when calculation was done using published data. The true power of the present study using the standard deviations of the measured EFs was 0.98. Thus, our study was sufficiently accurate to detect clinically relevant effects of a high-dose regimen of pantoprazole on left ventricular function.</p></sec><sec id="Sec20"><title>Implications for particular patients</title><p>Although healthy subjects may well tolerate high doses of pantoprazole, particular patients may be prone to cardiac side effects of PPIs. In isolated human and rabbit myocardium, pantoprazole has been shown to affect the contractile force by two mechanisms: (1) reduction in the amplitude of Ca<sup>2+</sup> transients as a consequence of impaired SR Ca<sup>2+</sup> uptake and reduced Ca<sup>2+</sup> influx via I<sub>Ca,L</sub> (2) reduced Ca<sup>2+</sup> responsiveness of the myofilaments as a result of a reduced maximal active tension and a slightly lower Ca<sup>2+</sup> sensitivity [<xref ref-type="bibr" rid="CR25">25</xref>]. In the end-stage failing human heart, development of contractile dysfunction is crucially caused by abnormalities of intracellular Ca<sup>2+</sup> cycling and sarcomeric proteins. Decreased expression and function of SR Ca<sup>2+</sup>&#x02013;ATPase, increased forward mode Na<sup>+</sup>&#x02013;Ca<sup>2+</sup> exchange activity as well, as dysfunction of the ryanodine receptor promoting impairment of systolic and diastolic Ca<sup>2+</sup> transients have been described [<xref ref-type="bibr" rid="CR13">13</xref>]. Moreover, dysfunctions of myofilaments that are probably caused by altered post-translational modification, in particular the phosphorylation state of troponins I and T and possibly myosin light chain, have been found [<xref ref-type="bibr" rid="CR20">20</xref>]. Hence, subcellular mechanisms underlying heart failure may be potentiated by treatment with high doses of pantoprazole. Further mechanisms of heart failure have been described [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Moreover, patients with heart failure are much more susceptible to negative inotropic drugs because of blunted contractile reserve subsequent to decreased sympathetic sensitivity [<xref ref-type="bibr" rid="CR1">1</xref>] or negative force&#x02013;frequency relationship [<xref ref-type="bibr" rid="CR13">13</xref>]. Furthermore, certain patients may have considerably higher plasma concentrations of PPIs. All PPIs undergo extensive hepatic biotransformation before elimination. In CYP2C19-poor metabolizers that represent approximately 3&#x02013;5% of Caucasians, a similar percentage of African&#x02013;Americans and 12&#x02013;25% of different Asian populations, much higher plasma concentrations and longer elimination half-lives have been found [<xref ref-type="bibr" rid="CR28">28</xref>]. The same holds true for patients with severe liver impairment [<xref ref-type="bibr" rid="CR8">8</xref>].</p></sec></sec><sec id="Sec21" sec-type="conclusion"><title>Conclusions</title><p>In conclusion, this study indicates that pantoprazole for injection is safe in healthy subjects with regard to cardiac contractile function when using a common high-dose regimen. Yet, it cannot be ruled out that ultra-high doses might impair function of normally beating hearts in vivo. Also, the effects of repetitive or continuous applications of high doses or application over prolonged periods have not been investigated for cardiac side effects in a prospective study. As long as there is no safety data, impairment of cardiac function should be taken into account in patients with heart failure or patients with combined heart and liver disease, as well as in particular situations like acute intoxication with ultra-high doses of pantoprazole. Moreover, in view of recent studies showing that appropriate use of intravenous PPIs was only seen in less than half of the patients [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], treatment with intravenous PPIs should be discontinued as soon as the patient is able to be treated with oral formulations.</p></sec></body><back><ack><p>We gratefully acknowledge the expert technical assistance of Mrs. Jutta Otto.</p><p><bold>Conflict of interest statement</bold> The authors declare that they have no conflicts of interest in connection with the submitted article. The authors had full control of all primary data and agree to allow the journal to review their data if requested.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bristow</surname><given-names>MR</given-names></name><name><surname>Ginsburg</surname><given-names>R</given-names></name><name><surname>Minobe</surname><given-names>W</given-names></name><name><surname>Cubicciotti</surname><given-names>RS</given-names></name><name><surname>Sageman</surname><given-names>WS</given-names></name><name><surname>Lurie</surname><given-names>K</given-names></name><name><surname>Billingham</surname><given-names>ME</given-names></name><name><surname>Harrison</surname><given-names>DC</given-names></name><name><surname>Stinson</surname><given-names>EB</given-names></name></person-group><article-title>Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts</article-title><source>New Engl J Med</source><year>1982</year><volume>307</volume><fpage>205</fpage><lpage>211</lpage></citation><citation citation-type="display-unstructured">Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. New Engl J Med 307:205&#x02013;211 <pub-id pub-id-type="pmid">6283349</pub-id></citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dellas</surname><given-names>C</given-names></name><name><surname>Hasenfuss</surname><given-names>G</given-names></name><name><surname>Vollmann</surname><given-names>D</given-names></name></person-group><article-title>Takotsubo cardiomyopathy with an unusual pattern of regional left ventricular wall motion abnormalities</article-title><source>Clin Res Cardiol</source><year>2007</year><volume>96</volume><fpage>389</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1007/s00392-007-0511-2</pub-id></citation><citation citation-type="display-unstructured">Dellas C, Hasenfuss G, Vollmann D (2007) Takotsubo cardiomyopathy with an unusual pattern of regional left ventricular wall motion abnormalities. Clin Res Cardiol 96:389&#x02013;392 <pub-id pub-id-type="pmid">17453139</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doughty</surname><given-names>RN</given-names></name><name><surname>Whalley</surname><given-names>GA</given-names></name><name><surname>Gamble</surname><given-names>G</given-names></name><name><surname>MacMahon</surname><given-names>S</given-names></name><name><surname>Sharpe</surname><given-names>N</given-names></name></person-group><article-title>Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease: Australia&#x02013;New Zealand Heart Failure Research Collaborative Group</article-title><source>J Am Coll Cardiol</source><year>1997</year><volume>29</volume><fpage>1060</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(97)00012-0</pub-id></citation><citation citation-type="display-unstructured">Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N (1997) Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease: Australia&#x02013;New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 29:1060&#x02013;1066 <pub-id pub-id-type="pmid">9120160</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DuBois</surname><given-names>D</given-names></name><name><surname>DuBois</surname><given-names>EF</given-names></name></person-group><article-title>A formula to estimate the approximate surface area if height and weight be known</article-title><source>Arch Intern Med</source><year>1916</year><volume>17</volume><fpage>863</fpage><lpage>871</lpage></citation><citation citation-type="display-unstructured">DuBois D, DuBois EF (1916) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:863&#x02013;871 </citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eschen</surname><given-names>O</given-names></name><name><surname>Fr&#x000f8;bert</surname><given-names>O</given-names></name><name><surname>Jensen</surname><given-names>V</given-names></name><name><surname>Hvitfeldt Poulsen</surname><given-names>S</given-names></name></person-group><article-title>Pheochromocytoma, a rare cause of acute cardiogenic shock</article-title><source>Clin Res Cardiol</source><year>2007</year><volume>96</volume><fpage>232</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1007/s00392-007-0496-x</pub-id></citation><citation citation-type="display-unstructured">Eschen O, Fr&#x000f8;bert O, Jensen V, Hvitfeldt Poulsen S (2007) Pheochromocytoma, a rare cause of acute cardiogenic shock. Clin Res Cardiol 96:232&#x02013;235 <pub-id pub-id-type="pmid">17361350</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="other">FDA statement (2007) FDA&#x02019;s safety reviews of Prilosec and Nexium find no evidence of increased rates of cardiac events. Available at <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/bbs/topics/NEWS/2007/NEW01754.html">http://www.fda.gov/bbs/topics/NEWS/2007/NEW01754.html</ext-link>. Cited 10 December 2007</citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferron</surname><given-names>GM</given-names></name><name><surname>McKeand</surname><given-names>W</given-names></name><name><surname>Mayer</surname><given-names>PR</given-names></name></person-group><article-title>Pharmacodynamic modeling of pantoprazole&#x02019;s irreversible effect on gastric acid secretion in humans and rats</article-title><source>J Clin Pharmacol</source><year>2001</year><volume>41</volume><fpage>149</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1177/00912700122009953</pub-id></citation><citation citation-type="display-unstructured">Ferron GM, McKeand W, Mayer PR (2001) Pharmacodynamic modeling of pantoprazole&#x02019;s irreversible effect on gastric acid secretion in humans and rats. J Clin Pharmacol 41:149&#x02013;156 <pub-id pub-id-type="pmid">11210394</pub-id></citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferron</surname><given-names>GM</given-names></name><name><surname>Preston</surname><given-names>RA</given-names></name><name><surname>Noveck</surname><given-names>RJ</given-names></name><name><surname>Pockros</surname><given-names>P</given-names></name><name><surname>Mayer</surname><given-names>P</given-names></name><name><surname>Getsy</surname><given-names>J</given-names></name><name><surname>Turner</surname><given-names>M</given-names></name><name><surname>Abell</surname><given-names>M</given-names></name><name><surname>Paul</surname><given-names>J</given-names></name></person-group><article-title>Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction</article-title><source>Clin Ther</source><year>2001</year><volume>23</volume><fpage>1180</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1016/S0149-2918(01)80100-4</pub-id></citation><citation citation-type="display-unstructured">Ferron GM, Preston RA, Noveck RJ, Pockros P, Mayer P, Getsy J, Turner M, Abell M, Paul J (2001) Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. Clin Ther 23:1180&#x02013;1192 <pub-id pub-id-type="pmid">11558857</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="other">GKV (2008) Arzneimittelschnellinformation. Available at <ext-link ext-link-type="uri" xlink:href="http://www.gkv-gamsi.de/Archiv_2008_1__Quartal.gkvnet">http://www.gkv-gamsi.de/Archiv_2008_1__Quartal.gkvnet</ext-link> of subordinate document. Cited July 15, 2008</citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gottdiener</surname><given-names>JS</given-names></name><name><surname>Bednarz</surname><given-names>J</given-names></name><name><surname>Devereux</surname><given-names>R</given-names></name><name><surname>Gardin</surname><given-names>J</given-names></name><name><surname>Klein</surname><given-names>A</given-names></name><name><surname>Manning</surname><given-names>WJ</given-names></name><name><surname>Morehead</surname><given-names>A</given-names></name><name><surname>Kitzman</surname><given-names>D</given-names></name><name><surname>Oh</surname><given-names>J</given-names></name><name><surname>Quinones</surname><given-names>M</given-names></name><name><surname>Schiller</surname><given-names>NB</given-names></name><name><surname>Stein</surname><given-names>JH</given-names></name><name><surname>Weissman</surname><given-names>NJ</given-names></name><collab>American Society of Echocardiography</collab></person-group><article-title>American Society of Echocardiography recommendations for use of echocardiography in clinical trials</article-title><source>J Am Soc Echocardiogr</source><year>2004</year><volume>17</volume><fpage>1086</fpage><lpage>1119</lpage></citation><citation citation-type="display-unstructured">Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, Morehead A, Kitzman D, Oh J, Quinones M, Schiller NB, Stein JH, Weissman NJ, American Society of Echocardiography (2004) American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 17:1086&#x02013;1119 <pub-id pub-id-type="pmid">15452478</pub-id></citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guda</surname><given-names>NM</given-names></name><name><surname>Noonan</surname><given-names>M</given-names></name><name><surname>Kreiner</surname><given-names>MJ</given-names></name><name><surname>Partington</surname><given-names>S</given-names></name><name><surname>Vakil</surname><given-names>N</given-names></name></person-group><article-title>Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage?</article-title><source>Am J Gastroenterol</source><year>2004</year><volume>99</volume><fpage>1233</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2004.30894.x</pub-id></citation><citation citation-type="display-unstructured">Guda NM, Noonan M, Kreiner MJ, Partington S, Vakil N (2004) Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage? Am J Gastroenterol 99:1233&#x02013;1237 <pub-id pub-id-type="pmid">15233659</pub-id></citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>SA</given-names></name><name><surname>Cigarroa</surname><given-names>CG</given-names></name><name><surname>Marcoux</surname><given-names>L</given-names></name><name><surname>Risser</surname><given-names>RC</given-names></name><name><surname>Grayburn</surname><given-names>PA</given-names></name><name><surname>Eichhorn</surname><given-names>EJ</given-names></name></person-group><article-title>Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade</article-title><source>J Am Coll Cardiol</source><year>1995</year><volume>25</volume><fpage>1154</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1016/0735-1097(94)00543-Y</pub-id></citation><citation citation-type="display-unstructured">Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ (1995) Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 25:1154&#x02013;1161 <pub-id pub-id-type="pmid">7897129</pub-id></citation></ref><ref id="CR13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hasenfuss</surname><given-names>G</given-names></name><name><surname>Pieske</surname><given-names>B</given-names></name></person-group><article-title>Calcium cycling in congestive heart failure</article-title><source>J Mol Cell Cardiol</source><year>2002</year><volume>34</volume><fpage>951</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1006/jmcc.2002.2037</pub-id></citation><citation citation-type="display-unstructured">Hasenfuss G, Pieske B (2002) Calcium cycling in congestive heart failure. J Mol Cell Cardiol 34:951&#x02013;969 <pub-id pub-id-type="pmid">12234765</pub-id></citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Himelman</surname><given-names>RB</given-names></name><name><surname>Cassidy</surname><given-names>MM</given-names></name><name><surname>Landzberg</surname><given-names>JS</given-names></name><name><surname>Schiller</surname><given-names>NB</given-names></name></person-group><article-title>Reproducibility of quantitative two-dimensional echocardiography</article-title><source>Am Heart J</source><year>1988</year><volume>115</volume><fpage>425</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1016/0002-8703(88)90491-7</pub-id></citation><citation citation-type="display-unstructured">Himelman RB, Cassidy MM, Landzberg JS, Schiller NB (1988) Reproducibility of quantitative two-dimensional echocardiography. Am Heart J 115:425&#x02013;431 <pub-id pub-id-type="pmid">3341178</pub-id></citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoppe</surname><given-names>UC</given-names></name></person-group><article-title>Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists?</article-title><source>Clin Res Cardiol</source><year>2007</year><volume>96</volume><fpage>196</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1007/s00392-007-0488-x</pub-id></citation><citation citation-type="display-unstructured">Hoppe UC (2007) Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists? Clin Res Cardiol 96:196&#x02013;198 <pub-id pub-id-type="pmid">17294351</pub-id></citation></ref><ref id="CR16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>GG</given-names></name><name><surname>Bates</surname><given-names>D</given-names></name><name><surname>McDonald</surname><given-names>D</given-names></name><name><surname>Panaccione</surname><given-names>R</given-names></name><name><surname>Romagnuolo</surname><given-names>J</given-names></name></person-group><article-title>Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions</article-title><source>Clin Gastroenterol Hepatol</source><year>2005</year><volume>3</volume><fpage>1207</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1016/S1542-3565(05)00757-3</pub-id></citation><citation citation-type="display-unstructured">Kaplan GG, Bates D, McDonald D, Panaccione R, Romagnuolo J (2005) Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions. Clin Gastroenterol Hepatol 3:1207&#x02013;1214 <pub-id pub-id-type="pmid">16361046</pub-id></citation></ref><ref id="CR17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kromer</surname><given-names>W</given-names></name><name><surname>Kruger</surname><given-names>U</given-names></name><name><surname>Huber</surname><given-names>R</given-names></name><name><surname>Hartmann</surname><given-names>M</given-names></name><name><surname>Steinijans</surname><given-names>VW</given-names></name></person-group><article-title>Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates</article-title><source>Pharmacology</source><year>1998</year><volume>56</volume><fpage>57</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1159/000028183</pub-id></citation><citation citation-type="display-unstructured">Kromer W, Kruger U, Huber R, Hartmann M, Steinijans VW (1998) Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology 56:57&#x02013;70 <pub-id pub-id-type="pmid">9494064</pub-id></citation></ref><ref id="CR18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>RM</given-names></name><name><surname>Bierig</surname><given-names>M</given-names></name><name><surname>Devereux</surname><given-names>RB</given-names></name><name><surname>Flachskampf</surname><given-names>FA</given-names></name><name><surname>Foster</surname><given-names>E</given-names></name><name><surname>Pellikka</surname><given-names>PA</given-names></name><name><surname>Picard</surname><given-names>MH</given-names></name><name><surname>Roman</surname><given-names>MJ</given-names></name><name><surname>Seward</surname><given-names>J</given-names></name><name><surname>Shanewise</surname><given-names>JS</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Spencer</surname><given-names>KT</given-names></name><name><surname>Sutton</surname><given-names>MS</given-names></name><name><surname>Stewart</surname><given-names>WJ</given-names></name></person-group><article-title>Recommendations for chamber quantification: a report from the American Society of Echocardiography&#x02019;s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography</article-title><source>J Am Soc Echocardiogr</source><year>2005</year><volume>18</volume><fpage>1440</fpage><lpage>1463</lpage><pub-id pub-id-type="doi">10.1016/j.echo.2005.10.005</pub-id></citation><citation citation-type="display-unstructured">Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography&#x02019;s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography. J Am Soc Echocardiogr 18:1440&#x02013;1463 <pub-id pub-id-type="pmid">16376782</pub-id></citation></ref><ref id="CR19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>JYW</given-names></name><name><surname>Sung</surname><given-names>JJY</given-names></name><name><surname>Lee</surname><given-names>KKC</given-names></name><name><surname>Yung</surname><given-names>MY</given-names></name><name><surname>Wong</surname><given-names>SK</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name><name><surname>Chan</surname><given-names>FK</given-names></name><name><surname>Ng</surname><given-names>EK</given-names></name><name><surname>You</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>CW</given-names></name><name><surname>Chan</surname><given-names>AC</given-names></name><name><surname>Chung</surname><given-names>SC</given-names></name></person-group><article-title>Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>310</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1056/NEJM200008033430501</pub-id></citation><citation citation-type="display-unstructured">Lau JYW, Sung JJY, Lee KKC, Yung MY, Wong SK, Wu JC, Chan FK, Ng EK, You JH, Lee CW, Chan AC, Chung SC (2000) Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 343:310&#x02013;316 <pub-id pub-id-type="pmid">10922420</pub-id></citation></ref><ref id="CR20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>LeWinter</surname><given-names>MM</given-names></name></person-group><article-title>Functional consequences of sarcomeric protein abnormalities in failing myocardium</article-title><source>Heart Fail Rev</source><year>2005</year><volume>10</volume><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1007/s10741-005-5254-4</pub-id></citation><citation citation-type="display-unstructured">LeWinter MM (2005) Functional consequences of sarcomeric protein abnormalities in failing myocardium. Heart Fail Rev 10:249&#x02013;257 <pub-id pub-id-type="pmid">16416047</pub-id></citation></ref><ref id="CR21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okabe</surname><given-names>S</given-names></name><name><surname>Amagase</surname><given-names>K</given-names></name><name><surname>Fujita</surname><given-names>H</given-names></name><name><surname>Iwata</surname><given-names>K</given-names></name><name><surname>Satake</surname><given-names>N</given-names></name><name><surname>Shibata</surname><given-names>S</given-names></name></person-group><article-title>Vasoinhibitory effect of leminoprazole, a H+, K(+)-ATPase inhibitor, on rat aortic rings</article-title><source>Gen Pharmacol</source><year>1996</year><volume>27</volume><fpage>117</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/0306-3623(95)00083-6</pub-id></citation><citation citation-type="display-unstructured">Okabe S, Amagase K, Fujita H, Iwata K, Satake N, Shibata S (1996) Vasoinhibitory effect of leminoprazole, a H+, K(+)-ATPase inhibitor, on rat aortic rings. Gen Pharmacol 27:117&#x02013;121 <pub-id pub-id-type="pmid">8742507</pub-id></citation></ref><ref id="CR22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qui&#x000f1;ones</surname><given-names>MA</given-names></name><name><surname>Otto</surname><given-names>CM</given-names></name><name><surname>Stoddard</surname><given-names>M</given-names></name><name><surname>Waggoner</surname><given-names>A</given-names></name><name><surname>Zoghbi</surname><given-names>WA</given-names></name></person-group><article-title>Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography</article-title><source>J Am Soc Echocardiogr</source><year>2002</year><volume>15</volume><fpage>167</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1067/mje.2002.120202</pub-id></citation><citation citation-type="display-unstructured">Qui&#x000f1;ones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA (2002) Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 15:167&#x02013;184 <pub-id pub-id-type="pmid">11836492</pub-id></citation></ref><ref id="CR23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rhoden</surname><given-names>KJ</given-names></name><name><surname>Tallini</surname><given-names>G</given-names></name><name><surname>Douglas</surname><given-names>JS</given-names></name></person-group><article-title>H<sup>+</sup>&#x02013;K<sup>+</sup> ATPase inhibitors cause relaxation of guinea pig and human airway smooth muscle in vitro</article-title><source>J Pharmacol Exp Ther</source><year>1996</year><volume>276</volume><fpage>897</fpage><lpage>903</lpage></citation><citation citation-type="display-unstructured">Rhoden KJ, Tallini G, Douglas JS (1996) H+&#x02013;K+ ATPase inhibitors cause relaxation of guinea pig and human airway smooth muscle in vitro. J Pharmacol Exp Ther 276:897&#x02013;903 <pub-id pub-id-type="pmid">8786567</pub-id></citation></ref><ref id="CR24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scharhag</surname><given-names>J</given-names></name><name><surname>Herrmann</surname><given-names>M</given-names></name><name><surname>Weissinger</surname><given-names>M</given-names></name><name><surname>Herrmann</surname><given-names>W</given-names></name><name><surname>Kindermann</surname><given-names>W</given-names></name></person-group><article-title>N-terminal B-type natriuretic peptide concentrations are similarly increased by 30 minutes of moderate and brisk walking in patients with coronary artery disease</article-title><source>Clin Res Cardiol</source><year>2007</year><volume>96</volume><fpage>218</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1007/s00392-007-0491-2</pub-id></citation><citation citation-type="display-unstructured">Scharhag J, Herrmann M, Weissinger M, Herrmann W, Kindermann W (2007) N-terminal B-type natriuretic peptide concentrations are similarly increased by 30 minutes of moderate and brisk walking in patients with coronary artery disease. Clin Res Cardiol 96:218&#x02013;226 <pub-id pub-id-type="pmid">17323015</pub-id></citation></ref><ref id="CR25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schillinger</surname><given-names>W</given-names></name><name><surname>Teucher</surname><given-names>N</given-names></name><name><surname>Sossalla</surname><given-names>S</given-names></name><name><surname>Kettlewell</surname><given-names>S</given-names></name><name><surname>Werner</surname><given-names>C</given-names></name><name><surname>Raddatz</surname><given-names>D</given-names></name><name><surname>Elgner</surname><given-names>A</given-names></name><name><surname>Tenderich</surname><given-names>G</given-names></name><name><surname>Pieske</surname><given-names>B</given-names></name><name><surname>Ramadori</surname><given-names>G</given-names></name><name><surname>Sch&#x000f6;ndube</surname><given-names>FA</given-names></name><name><surname>K&#x000f6;gler</surname><given-names>H</given-names></name><name><surname>Kocksk&#x000e4;mper</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>LS</given-names></name><name><surname>Schw&#x000f6;rer</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>GL</given-names></name><name><surname>Hasenfuss</surname><given-names>G</given-names></name></person-group><article-title>Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms</article-title><source>Circulation</source><year>2007</year><volume>116</volume><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.666008</pub-id></citation><citation citation-type="display-unstructured">Schillinger W, Teucher N, Sossalla S, Kettlewell S, Werner C, Raddatz D, Elgner A, Tenderich G, Pieske B, Ramadori G, Sch&#x000f6;ndube FA, K&#x000f6;gler H, Kocksk&#x000e4;mper J, Maier LS, Schw&#x000f6;rer H, Smith GL, Hasenfuss G (2007) Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms. Circulation 116:57&#x02013;66 <pub-id pub-id-type="pmid">17576869</pub-id></citation></ref><ref id="CR26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>M</given-names></name><name><surname>Schmoldt</surname><given-names>A</given-names></name></person-group><article-title>Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics</article-title><source>Pharmazie</source><year>2003</year><volume>58</volume><fpage>447</fpage><lpage>474</lpage></citation><citation citation-type="display-unstructured">Schulz M, Schmoldt A (2003) Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58:447&#x02013;474 <pub-id pub-id-type="pmid">12889529</pub-id></citation></ref><ref id="CR27"><label>27.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Senn</surname><given-names>S</given-names></name></person-group><source>Cross-over trials in clinical research</source><year>1993</year><publisher-loc>Chichester</publisher-loc><publisher-name>Wiley</publisher-name></citation><citation citation-type="display-unstructured">Senn S (1993) Cross-over trials in clinical research. Wiley, Chichester </citation></ref><ref id="CR28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Klotz</surname><given-names>U</given-names></name></person-group><article-title>Proton pump inhibitors: an update on their clinical use and pharmacokinetics</article-title><source>Eur J Clin Pharmacol</source><year>2008</year><volume>64</volume><fpage>935</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1007/s00228-008-0538-y</pub-id></citation><citation citation-type="display-unstructured">Shi S, Klotz U (2008) Proton pump inhibitors: an update on their clinical use and pharmacokinetics. Eur J Clin Pharmacol 64:935&#x02013;951 <pub-id pub-id-type="pmid">18679668</pub-id></citation></ref><ref id="CR29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horst</surname><given-names>IC</given-names></name><name><surname>Voors</surname><given-names>AA</given-names></name><name><surname>Veldhuisen</surname><given-names>DJ</given-names></name></person-group><article-title>Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?</article-title><source>Clin Res Cardiol</source><year>2007</year><volume>96</volume><fpage>193</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1007/s00392-007-0487-y</pub-id></citation><citation citation-type="display-unstructured">van der Horst IC, Voors AA, van Veldhuisen DJ (2007) Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists? Clin Res Cardiol 96:193&#x02013;195 <pub-id pub-id-type="pmid">17294352</pub-id></citation></ref><ref id="CR30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rensburg</surname><given-names>CJ</given-names></name><name><surname>Hartmann</surname><given-names>M</given-names></name><name><surname>Thorpe</surname><given-names>A</given-names></name><name><surname>Venter</surname><given-names>L</given-names></name><name><surname>Theron</surname><given-names>I</given-names></name><name><surname>L&#x000fc;hmann</surname><given-names>R</given-names></name><name><surname>Wurst</surname><given-names>W</given-names></name></person-group><article-title>Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer</article-title><source>Am J Gastroenterol</source><year>2003</year><volume>98</volume><fpage>2635</fpage><lpage>2641</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2003.08723.x</pub-id></citation><citation citation-type="display-unstructured">van Rensburg CJ, Hartmann M, Thorpe A, Venter L, Theron I, L&#x000fc;hmann R, Wurst W (2003) Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer. Am J Gastroenterol 98:2635&#x02013;2641 <pub-id pub-id-type="pmid">14687809</pub-id></citation></ref></ref-list></back></article>


